BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19, 2025

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18, 2025

The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

May 17th 2025

By Skylar Jeremias

Article

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.

The Top 5 Biosimilar Articles for the Week of May 12

May 16th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 12, 2025.

Follow-On Biologics Poised to Expand Global Health Care Access and Lower Costs

May 15th 2025

By Cameron Santoro

Article

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs and expanding treatment access.

Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

May 15th 2025

By Melissa Garcia, PharmD Candidate

Article

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA

May 13th 2025

By Skylar Jeremias

Article

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.

Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics

May 13th 2025

By Skylar Jeremias

Article

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

May 11th 2025

By Cameron Santoro

Video

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs

May 10th 2025

By Deana Ferreri, PhD

Article

Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias

Article

The Top 5 Biosimilar Articles for the Week of May 5

May 9th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 5, 2025.